Market Overview:
The global bile duct cancer therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of bile duct cancer, rising awareness about available treatment options, and the launch of novel therapies. Based on type, the global bile duct cancer therapeutics market can be segmented into mecine, surgery, and other therapies. The mecine segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to increasing use of targeted therapies and immunotherapies for treating bile duct cancer patients globally. Based on application, hospitals are expected to account for the largest share of the global market in 2018 followed by clinics and other applications segments respectively.
Product Definition:
Bile duct cancer is a rare type of cancer that affects the bile ducts. The bile ducts are tubes that carry bile from the liver to the gallbladder and small intestine. Bile is a fluid made by the liver that helps digest food. Bile duct cancer may cause yellowing of the skin and whites of the eyes (jaundice), itching, weight loss, and abdominal pain.
There are several types of treatments for bile duct cancer, including surgery, radiation therapy, chemotherapy, and targeted therapies. Surgery is often used to remove tumors from the biliary tract. Radiation therapy may be used before or after surgery to help kill any remaining tumor cells. Chemotherapy uses drugs to kill tumor cells throughout the body.
Mecine:
Mecine is a bio-active component of the essential oil obtained from several plants, including clove, eucalyptus and oregano. The mechanism by which it exerts its anticancer effect involves interference with the cell cycle at G1/G2 phase and arrest cell growth.
It also blocks an enzyme called topoisomerase II that controls DNA replication.
Surgery:
Bile duct cancer (BDC) is a type of cancer that begins with the bile duct, which carries bile juice from the liver to the intestine. Biliary tract cancers are among one of the most common types of gastrointestinal malignancies. The exact cause of this disease is still unknown; however, research studies have shown that it may be due to multiple factors such as infection in the biliary system or genetic mutations.
Application Insights:
The other application segment dominated the global market in 2017. This can be attributed to the increasing prevalence of chronic liver diseases and bile duct cancer across various regions, such as North America and Europe. According to data published by the NCBI, around 90% of bile duct cancers occur in patients with cirrhosis or chronic liver disease. Thus, there is a high unmet medical need for effective treatment options for these patients.
Based on application, the global market has been segmented into hospitals/clinics (North America), other (Europe & Asia Pacific) and private practice settings (Middle East & Africa). Hospitals/clinics held a major share in terms of revenue as well as volume in 2017 owing to factors such as rising incidence rates of hepatic disorders coupled with advanced healthcare facilities offering specialized services for treating Biliary Duct Cancer (BDC).
Regional Analysis:
North America dominated the global market in 2017. High incidence rate of liver cancer and advanced healthcare infrastructure are some factors responsible for its large share. In addition, rising adoption of new technologies and increasing government funding for research & development activities are also contributing to its largest share.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China, India, South Korea, Singapore and Thailand. Moreover, growing medical tourism industry due to affordable treatment cost is also anticipated boost regional growth over the forecast period.
Growth Factors:
- Increasing incidence of bile duct cancer
- Growing demand for better and more effective therapies for the treatment of bile duct cancer
- Rising awareness about available treatment options for bile duct cancer
- Technological advancements in the field of bile duct cancer therapeutics
- increasing investment in research and development activities for the development of novel therapies for the treatment of bile duct cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Bile Duct Cancer Therapeutics Market Research Report
By Type
Mecine, Surgery, Other
By Application
Hospitals, Clinics, Other
By Companies
Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Teva Pharmaceutical, Eli Lilly and Company, Sanofi, Fresenius Kabi, Mylan, Delcath Systems, Accord Healthcare, Intercept Pharmaceuticals, Celgene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Bile Duct Cancer Therapeutics Market Report Segments:
The global Bile Duct Cancer Therapeutics market is segmented on the basis of:
Types
Mecine, Surgery, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- Teva Pharmaceutical
- Eli Lilly and Company
- Sanofi
- Fresenius Kabi
- Mylan
- Delcath Systems
- Accord Healthcare
- Intercept Pharmaceuticals
- Celgene
Highlights of The Bile Duct Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Mecine
- Surgery
- Other
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bile Duct Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bile duct cancer therapeutics is a term used to describe treatments for bile duct cancer. These treatments may include surgery, chemotherapy, and radiation therapy.
Some of the major players in the bile duct cancer therapeutics market are Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Teva Pharmaceutical, Eli Lilly and Company, Sanofi, Fresenius Kabi, Mylan, Delcath Systems, Accord Healthcare, Intercept Pharmaceuticals, Celgene.
The bile duct cancer therapeutics market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Bile Duct Cancer Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Bile Duct Cancer Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Bile Duct Cancer Therapeutics Market - Supply Chain
4.5. Global Bile Duct Cancer Therapeutics Market Forecast
4.5.1. Bile Duct Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Bile Duct Cancer Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Bile Duct Cancer Therapeutics Market Absolute $ Opportunity
5. Global Bile Duct Cancer Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Type
5.3.1. Mecine
5.3.2. Surgery
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Bile Duct Cancer Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Bile Duct Cancer Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Bile Duct Cancer Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Bile Duct Cancer Therapeutics Demand Share Forecast, 2019-2026
9. North America Bile Duct Cancer Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Type
9.7.1. Mecine
9.7.2. Surgery
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Bile Duct Cancer Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Bile Duct Cancer Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Type
10.7.1. Mecine
10.7.2. Surgery
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Bile Duct Cancer Therapeutics Demand Share Forecast, 2019-2026
11. Europe Bile Duct Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Type
11.7.1. Mecine
11.7.2. Surgery
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9.Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Bile Duct Cancer Therapeutics Demand Share, 2019-2026
12. Asia Pacific Bile Duct Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Type
12.7.1. Mecine
12.7.2. Surgery
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Bile Duct Cancer Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Bile Duct Cancer Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Bile Duct Cancer Therapeutics Market Size and Volume Forecast by Type
13.7.1. Mecine
13.7.2. Surgery
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Bile Duct Cancer Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Bile Duct Cancer Therapeutics Market: Market Share Analysis
14.2. Bile Duct Cancer Therapeutics Distributors and Customers
14.3. Bile Duct Cancer Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. F. Hoffmann-La Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Eli Lilly and Company
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Fresenius Kabi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Delcath Systems
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Accord Healthcare
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Intercept Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Celgene
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
